1 day Ago By ABMN Staff
Forte Biosciences, Inc. ( NASDAQ:FBRX – Get Free Report ) was the recipient of unusually large options trading on Wednesday. Traders acquired 30,205 call options on the stock.
This represents an increase of approximately 1,663% compared to the average volume of 1,713 call options. Analyst Upgrades and Downgrades FBRX has been the topic of a number of recent analyst reports. Chardan Capital restated a “buy” rating and issued a $0.
12 price target on shares of Forte Biosciences in a research report on Monday, August 19th. Brookline Capital Management initiated coverage on Forte Biosciences in a research report on Thursday, May 30th. They issued a “buy” rating and a $0.
16 price target on the stock. Read Our Latest Analysis on Forte Biosciences Institutional Trading of Forte Biosciences Forte Biosciences Stock Down 5.1 % NASDAQ:FBRX opened at $6.
73 on Thursday. The stock’s 50-day simple moving average is $2.22 and its 200 day simple moving average is $0.
78. The firm has a market capitalization of $9.83 million and a PE ratio of -7.
65. Forte Biosciences has a twelve month low of $6.50 and a twelve month high of $21.
25. Forte Biosciences ( NASDAQ:FBRX – Get Free Report ) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.
01) earnings per share for the quarter, meeting the consensus estimate of ($0.01). On average, analysts anticipate that Forte Biosciences will post -22.
5 EPS for the current fiscal year. Forte Biosciences Company Profile ( Get Free Report ) Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata.
Forte Biosciences, Inc is headquartered in Dallas, Texas. Read More Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
